Asterias Biotherapeutics (AST) Tops Q1 EPS by 5c

Asterias Biotherapeutics (NYSE: AST) reported Q1 EPS of ($0.13), $0.05 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $2.01 million versus the consensus estimate of $1.52 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M